Acalabrutinib Plus Venetoclax/Obinutuzumab Demonstrates Efficacy, Safety in Mantle Cell Lymphoma
Acalabrutinib plus venetoclax and obinutuzumab demonstrated antitumor activity with a manageable safety profile in mantle cell lymphoma.
Related Articles
Lete-Cel Generates Durable Responses in Synovial Sarcoma and Myoxid/Round Cell Liposarcoma
Patients with metastatic myxoid/round cell liposarcoma or synovial sarcoma expressing NY-ESO-1 and HLA achieved an ORR of 42% with lete-cel.
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
Ma et al. identify P4HA1 as a critical regulator of CD8+ T cell activity in solid tumor microenvironment. P4HA1 induction in CD8+ T cells causes mitochondrial dysfunction and…
AI accurately identifies targetable alterations in lung cancer histological images
Nature Reviews Clinical Oncology – DeepGEM, an artificial intelligence (AI)-based model, accurately predicts the presence of key genomic alterations in histological slides prepared from samples…
APP Lifetime Achievement Award – Tandem Meetings News
This year’s recipient of the APP Lifetime Achievement Award, Sameeya Ahmed-Winston, CPNP, CPHON, BMTCN, shares insights and her outlook on being an advanced practice provider…
Dry January is over. Now what? Preventing 7 types of cancer by cutting alcohol: HealthLink
A Fred Hutch cancer epidemiologist highlights alcohol’s cancer link during Cancer Prevention Month.
World Cancer Day Shines Light on Therapeutic Advancements in Cancer Care
Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and improving patient outcomes.
Dr Moore on the 2024 FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer
Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.
Epirubicin/Mindfulness Intervention Improved Outcomes in Urinary Tumor Patients – Oncology Nurse Advisor
Researchers compared the effects of conventional treatment with a combination of epirubicin and mindfulness intervention on oncologic and psychologic burden in patients with urinary tract…
Pembrolizumab Provides “Robust” Clinical Benefit in Clear Cell Gynecologic Cancer
“Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.
The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.